ValiRx Enters Strategic Agreement with McGill and IRICoR for RNA Helicase Inhibitor Development

ValiRx signs nine-month evaluation deal with McGill and IRICoR for an RNA helicase cancer drug

ValiRx has kicked off a nine-month Evaluation and Material Transfer Agreement with McGill University and IRICoR to assess a second-generation, orally available RNA helicase inhibitor. In plain English: they’re testing whether this promising anti-cancer pill hits its target and packs enough punch to progress.

The work will be run by Inaphaea Biolabs, ValiRx’s wholly owned lab subsidiary. Crucially, any data generated during the evaluation (the “Evaluation Results”) will belong to ValiRx. That IP positioning is a smart starting point.

Who’s doing what and why it matters

McGill and IRICoR have already advanced this RNA helicase asset to a relatively late preclinical stage, according to the commentary. Inaphaea will now confirm target engagement (does the drug bind the intended protein in the right way?) and potency (how much is needed to get the desired effect).

A few quick definitions:

• Material Transfer Agreement (MTA) – a contract to share materials and data for research.
• RNA helicase inhibitor – a drug designed to block enzymes that unwind RNA, potentially disrupting cancer cell survival.
• Orally available – can be taken as a pill rather than an infusion, generally more convenient and market-friendly.

The Company highlights opportunities in both human and veterinary health. That could broaden the commercial scope, though exact indications and markets are not disclosed.

NewCo structure: asset-level commercialisation and an equity option for ValiRx

IRICoR will set up a new Canadian subsidiary (“NewCo”) to commercialise both the Evaluation Results and the existing background IP (the Institutions’ pre-existing intellectual property). NewCo will receive an exclusive, worldwide, sub-licensable licence to that background IP, meaning it can license it onward to partners.

Once the evaluation is done, ValiRx has an option to license its Evaluation Results into NewCo in exchange for a 15% equity stake, on pre-agreed terms (the detailed terms are not disclosed). This is a classic venture-style structure designed to move a single asset forward without heavy dilution at the plc level.

Funding plan: up to £2 million seed, plus external capital

NewCo will seek both non-dilutive funding (e.g. grants) and dilutive funding (equity). ValiRx, and potentially co-investors it arranges, may provide up to £2 million of seed funding, in tranches aligned with NewCo’s cash needs. In return, ValiRx would receive further equity, guided by a development plan provided by the Company.

All funding other than this Seed Funding will dilute all shareholders on a pari passu basis (i.e. pro rata, equally across share classes). The message: bring in outside money to push the asset forward while ring-fencing dilution at the NewCo level rather than at ValiRx plc.

Downside protection: 1.5x payback if ValiRx declines the equity route

If, within 30 days of finishing the evaluation, ValiRx decides not to license the results into NewCo for equity, the rights to the Evaluation Results revert to the Institutions. If they then commercialise the technology at any time after the evaluation, ValiRx is due a cash payment equal to 1.5x its total investment, estimated at no more than £150,000. That’s modest cash-back protection that limits downside on the evaluation spend.

Why RNA helicase inhibitors are interesting

RNA helicases are enzymes that manage the structure and processing of RNA, a critical step in how cells function and how cancers propagate. Inhibiting these enzymes can disrupt tumour growth pathways. A “second-generation” molecule implies improvements over earlier candidates – potentially better selectivity, potency, or safety – and being orally available is a commercial plus.

ValiRx notes it has completed extensive due diligence on technical, clinical and commercial positioning. The exact preclinical package hasn’t been disclosed, but the tone suggests this is later-stage than some of ValiRx’s historic assets.

Strategic fit: later-stage assets and Inaphaea’s role

This deal neatly aligns with management’s pivot towards higher-quality, later-stage assets closer to the clinic. It also leans on Inaphaea’s capabilities. By running the evaluation internally, ValiRx keeps control of the data and timelines. It’s not stated whether Inaphaea will generate external revenue from this work, but value clearly accrues to ValiRx through ownership of the Evaluation Results.

The asset-level NewCo approach is notable. Diluting an individual programme, rather than the plc, can be shareholder-friendly – provided ValiRx maintains meaningful exposure to the upside and does not overcommit cash.

Key numbers at a glance

Evaluation period	Nine months
Ownership of Evaluation Results	ValiRx
Equity option in NewCo	15% (on completion of evaluation, under pre-agreed terms)
Potential Seed Funding by ValiRx	Up to £2 million (in tranches, for further equity)
Decision window if not proceeding	30 days post-evaluation
Downside protection	1.5x cash payment on ValiRx’s total evaluation investment (estimated at no more than £150,000)

What to watch next

• Start of evaluation work at Inaphaea and any interim updates – timelines beyond the nine months are not disclosed.
• Formation of NewCo by IRICoR and initial governance details – not disclosed in the RNS.
• Data readout after nine months, followed by ValiRx’s 30-day decision on the 15% equity option.
• External funding progress for NewCo and any ValiRx-led seed tranche commitments.
• Clarity on target indications in human and veterinary markets.

Risks and open questions

• Scientific risk: target engagement and potency need to be confirmed; no efficacy or safety data are disclosed here.
• Stage specifics: despite “later stage” language, precise development stage, datasets and timelines to clinic are not disclosed.
• Economics: valuation terms for the 15% equity, future equity pricing, and governance rights are not disclosed.
• Funding: ValiRx “may” invest up to £2 million; availability of funds is a factor. External funding appetite will influence dilution at NewCo.
• IP scope: the exact contours of Background Intellectual Property licensed to NewCo are not detailed.

My take: structured, asset-level upside with sensible guardrails

This is a tidy piece of deal-making. ValiRx keeps ownership of the evaluation data, secures a clear path to equity in a dedicated NewCo, and creates room for outside capital to share the load. The 1.5x payback on a sub-£150,000 evaluation budget won’t make anyone rich, but it de-risks the immediate spend.

The big swing factor is the quality of the nine-month data. If Inaphaea demonstrates compelling target engagement and potency for an oral, second-generation RNA helicase inhibitor, NewCo could be partnerable or fundable on decent terms. If not, the fallback is limited downside and useful learnings. On balance, this feels positive and consistent with ValiRx’s strategy to get closer to clinic without diluting the plc at every turn.

Engage with management

ValiRx invites investor questions via its hub: https://valirx.com/s/cc8ef3. Company site: www.valirx.com.